SCHEMBL12173597

SCHEMBL12173597

CC(C)(C)c1ccc(-c2ccc(C(C)(C)C)cc2C#N)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 2/20 0.53
▸ XDH P47989 1/20 0.40
▸ PTPN5 P54829 1/20 0.40
▸ ALOX5AP P20292 1/20 0.39
▸ FEN1 P39748 1/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ PLA2G1B P04054 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ CASP3 P42574 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ SENP8 Q96LD8 1/20 0.38
▸ SENP7 Q9BQF6 1/20 0.38
▸ SENP6 Q9GZR1 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ ATG4B Q9Y4P1 1/20 0.38
▸ ESR2 Q92731 1/20 0.38
▸ STS P08842 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26179240 0.96 KIF11 (0.50) KIF11XDHPTPN5ALOX5APFEN1
SCHEMBL15853159 0.89 ALDH1A1 (0.43) KIF11XDHPTPN5NPC1RAB9A
SCHEMBL30395197 0.85 KIF11 (0.57) KIF11XDHPTPN5NPC1RAB9A
SCHEMBL19797926 0.81 ESR2 (0.59) KIF11PTPN5ALDH1A1ESR2TRPV1
SCHEMBL25708832 0.79 MGAT2 (0.38) KIF11XDHNPC1ALDH1A1LMNA
SCHEMBL497451 0.78 KIF11 (0.47) KIF11XDHALDH1A1
SCHEMBL30566936 0.78 KIF11 (0.47) KIF11XDHALDH1A1
SCHEMBL15832009 0.77 KIF11 (0.49) KIF11XDHPTPN5ALDH1A1
SCHEMBL24617123 0.77 KIF11 (0.49) KIF11PTPN5ESR2TRPV1
SCHEMBL17708066 0.77 KIF11 (0.42) KIF11NPC1RAB9AALDH1A1PLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133170-B2 Inhibitors of HCV NS5A HOFFMANN-LA ROCHE INC. (US) 2015-09-15 — — US disclosed
US-20150166514-A1 INHIBITORS OF HCV NS5A HOFFMANN-LA ROCHE INC. (US) 2015-06-18 — — US disclosed
US-20120328565-A1 ANTIVIRAL COMPOUNDS BRINKMAN JOHN A (US) 2012-12-27 — — US disclosed
US-20120230951-A1 ANTIVIRAL COMPOUNDS ALAM MUZAFFAR (US) 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120328565-A1 ANTIVIRAL COMPOUNDS EIF2AK2, HAVCR2, MAVS KIF11 2785/4885XDH 202/4885PTPN5 2112/4885
US-20120230951-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS KIF11 3013/4885XDH 536/4885PTPN5 2936/4885
US-20150166514-A1 INHIBITORS OF HCV NS5A HAVCR2, EIF2AK2, MAVS KIF11 3031/4885XDH 3273/4885PTPN5 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback